Roth MKM analyst Richard Baldry lowered the firm’s price target on OptimizeRx (OPRX) to $16 from $20 and keeps a Buy rating on the shares. The company’s Q3 result was again light on revenues as its direct-to-consumer segment saw a material shift away from more expensive managed services to self-service, the analyst tells investors in a research note. 2024 is seen as a “lost year” for OptimizeRx, though the firm expects 2025 breakouts for both revenues and earnings as DAAP revenues scale, Roth added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx price target lowered to $8 from $16 at JMP Securities
- OptimizeRx price target lowered to $5 from $11 at Barclays
- OptimizeRx Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Tetra Tech down 8% after Q4 results, guidance
- OptimizeRx sees FY24 revenue $88M-$92M , consensus $100.69M